Ultragenyx Pharmaceutical Inc. (RARE) Issues Earnings Results
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($1.87), Bloomberg Earnings reports. The business had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.02 million. During the same quarter last year, the firm posted ($1.64) EPS. The company’s revenue was up 81.8% compared to the same quarter last year.
In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis acquired 7,500 shares of the company’s stock in a transaction that occurred on Monday, August 28th. The shares were acquired at an average price of $52.52 per share, with a total value of $393,900.00. Following the purchase, the chief executive officer now owns 430,569 shares of the company’s stock, valued at approximately $22,613,483.88. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 9.20% of the company’s stock.
WARNING: “Ultragenyx Pharmaceutical Inc. (RARE) Issues Earnings Results” was posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/11/02/ultragenyx-pharmaceutical-inc-rare-issues-earnings-results.html.
A number of research analysts have issued reports on RARE shares. Canaccord Genuity reiterated a “buy” rating and set a $83.00 price target (down previously from $98.00) on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, August 22nd. BidaskClub upgraded Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Tuesday, July 25th. Stifel Nicolaus reiterated a “buy” rating and set a $85.00 price target (down previously from $95.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 23rd. J P Morgan Chase & Co set a $76.00 price target on Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday, August 23rd. Finally, Robert W. Baird reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 19th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $71.94.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.